Spero Therapeutics Focuses on Tebipenem HBr Program
Spero Therapeutics reported a Q3 net loss of $7.4 million, down from $17.1 million in 2024, with revenues of $5.4 million. The company is focusing on its tebipenem HBr program after a successful Phase 3 trial, ceasing other projects to collaborate with GSK. Spero aims for regulatory approval and commercialization, needing more funding but optimistic about market acceptance.
Spero Therapeutics ( (SPRO) ) has released its Q3 earnings. Here is a breakdown of the information Spero Therapeutics presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for rare diseases and multi-drug resistant bacterial infections. The company is primarily engaged in advancing its tebipenem HBr program, which targets complicated urinary tract infections.
In its latest earnings report, Spero Therapeutics highlighted the completion of a successful Phase 3 trial for tebipenem HBr, which met its primary endpoint and was stopped early for efficacy. The company also announced a strategic shift, ceasing development of its SPR720 and SPR206 programs to focus resources on the tebipenem HBr program and its collaboration with GlaxoSmithKline (GSK).
Financially, Spero reported a net loss of $7.4 million for the third quarter of 2025, a decrease from the $17.1 million loss in the same period of 2024. Total revenues for the quarter were $5.4 million, down from $13.5 million in the previous year, reflecting a decrease in grant and collaboration revenues. The company ended the quarter with $48.6 million in cash and cash equivalents, down from $52.9 million at the end of 2024.
Looking ahead, Spero Therapeutics remains focused on advancing the tebipenem HBr program through regulatory approval and commercialization, with GSK planning to submit data to the FDA in the fourth quarter of 2025. The company anticipates needing additional funding to support its operations and development efforts but is optimistic about the potential market acceptance of its lead product candidate.
